A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

被引:45
|
作者
Pantuck, A. J. [1 ]
Pettaway, C. A. [2 ]
Dreicer, R. [3 ]
Corman, J. [4 ]
Katz, A. [5 ]
Ho, A. [5 ]
Aronson, W. [1 ,6 ]
Clark, W. [7 ]
Simmons, G. [8 ]
Heber, D. [1 ,9 ]
机构
[1] Univ Calif Los Angeles, Dept Urol, Inst Urol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Winthrop Univ Hosp, Garden City, NY USA
[6] VA Med Ctr Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[7] Alaska Clin Res Ctr, Anchorage, AK USA
[8] Five Valleys Urol, Missoula, MT USA
[9] Univ Calif Los Angeles, Dept Med & Clin Nutr, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
MANGANESE SUPEROXIDE-DISMUTASE; FACTOR-KAPPA-B; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; PHASE-II; GROWTH; CARCINOGENESIS; RADIATION; JUICE; RISK;
D O I
10.1038/pcan.2015.32
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. METHODS: Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. RESULTS: One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2: 1 (extract N = 102; placebo N = 64; juice N = 17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P < 0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004). However, none of these changes were statistically significant between the three groups (P > 0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P = 0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P = 0.03). CONCLUSIONS: Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [41] Fluctuations in blood lipid levels during furosemide therapy - A randomized, double-blind, placebo-controlled crossover study
    Campbell, N
    Brant, R
    Stalts, H
    Stone, J
    Mahallati, H
    ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (13) : 1461 - 1463
  • [42] Donepezil for cancer fatigue: A double-blind, randomized, placebo-controlled trial
    Bruera, Eduardo
    El Osta, Badi
    Valero, Vicente
    Driver, Larry C.
    Pei, Be-Lian
    Shen, Loren
    Poulter, Valerie A.
    Palmer, J. Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3475 - 3481
  • [43] A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men
    Sigurdsson, Steinthor
    Geirsson, Gudmundur
    Gudmundsdottir, Hrefna
    Egilsdottir, Perla B.
    Gudbjarnason, Sigmundur
    SCANDINAVIAN JOURNAL OF UROLOGY, 2013, 47 (01) : 26 - 32
  • [44] Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study
    Nickel, M.
    Moleda, D.
    Loew, T.
    Rother, W.
    Gil, F. Pedrosa
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2007, 19 (01) : 104 - 107
  • [45] Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study
    M Nickel
    D Moleda
    T Loew
    W Rother
    F Pedrosa Gil
    International Journal of Impotence Research, 2007, 19 : 104 - 107
  • [46] Donepezil for cancer-related fatigue: A double-blind, randomized, placebo-controlled study
    Bruera, E.
    El Osta, B.
    Valero, V.
    Driver, L.
    Palmer, J.
    Pei, B.
    Shen, L.
    Poulter, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial
    Savard, Josee
    Moussa, Hanane
    Pelletier, Jean-Francois
    Julien, Pierre
    Lacombe, Louis
    Tiguert, Rabi
    Caumartin, Yves
    Dujardin, Thierry
    Toren, Paul
    Pouliot, Frederic
    Lodde, Michele
    Fradet, Yves
    Robitaille, Karine
    Fradet, Vincent
    CANCER MEDICINE, 2023, 12 (19): : 20163 - 20176
  • [48] Quisqualis indica extract for men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled trial
    Shin, Dongho
    Zhu, Guan Qun
    Tian, Wen Jie
    Ahn, Sun Tae
    Jeon, Seung Hwan
    Cho, Hyuk Jin
    Ha, U-Syn
    Hong, Sung-Hoo
    Lee, Ji Youl
    Kim, Sae Woong
    Moon, Du Geon
    Bae, Woong Jin
    INVESTIGATIVE AND CLINICAL UROLOGY, 2023, 64 (01) : 20 - 30
  • [49] Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study
    Lukkarinen, O
    Lehtonen, T
    Talja, M
    Lundstedt, S
    Tiitinen, J
    Taari, K
    ANNALES CHIRURGIAE ET GYNAECOLOGIAE, 1999, 88 (04) : 299 - 303
  • [50] Randomized, double-blind and placebo-controlled study of the immunomodulatory effects of Lingzhi in children with cancers
    Shing, M. K.
    Leung, T. F.
    Chu, Y. L.
    Li, C. Y.
    Chik, K. W.
    Leung, P. C.
    Lee, V.
    Yuen, P. M.
    Li, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)